Dose Reduction in Antipsychotics and Its Risks

Reducing the dosage of antipsychotics in schizophrenia has been a contentious issue, as recent studies show no significant improvement in social functioning from such reductions. A comprehensive two-year study involving 19 centers in England indicated that while initial hopes rested on finding benefits from tapering medications, the results demonstrated a marked increase in hospitalizations for those with reduced dosages. With rates rising to 39% compared to 16% for stable doses, it became evident that the risks outweighed any potential benefits. The need for longer studies that extend beyond two years was highlighted, as previous research with longer follow-ups suggested the possibility of functional improvements over time.